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Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. 
Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials 
have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic 
drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. 
In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since 2013, 10 
epilepsy centers in America have conducted research regarding the efficacy of cannabis to treat 
epilepsy. Cannabis has many components, including cannabidiol (CBD) and Δ9-tetrahydrocannabinol 
(THC). THC has psychoactive properties exerted through its binding of the cannabinoid receptor (CBR) 
whereas CBD is a CBR antagonist. The inhibition of epilepsy by CBD may therefore be caused by 
various mechanisms, although the detailed mechanisms of CBD actions have not yet been well defined. 
In most studies, trial doses of CBD were 2-5 mg/kg/day. Several such studies have shown that CBD 
does have efficacy for treatment of epilepsy. Reported adverse effects of CBD were mostly mild, 
including drowsiness, diarrhea, and decreased appetite. Severe adverse reactions requiring treatment, 
such as status epilepticus, have also been reported but it is not clear that this is related to CBD. 
Furthermore, many previous studies have been limited by an open-label or survey design. In future, 
double-blind, controlled trials are required and the use of CBD to treat other neurological problems 
should also be investigated. (2017;7:16-20)
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Introduction
Epilepsy impacts the brain, and is associated with cognitive dys-
function and behavior disorder, which can affect quality of life, espe-
cially during the developmental period.1-3 Early onset epilepsy, partic-
ularly in those less than 3 years old, and uncontrolled seizures are as-
sociated with poor cognitive function later in life.4 
Currently, more than 20 different antiepileptic drugs (AED) exist 
for the treatment of epilepsy. However, 30% of patients with epi-
lepsy continue to have seizures.5-7 Many new medications have been 
approved in the past two decades, but these have not reduced the 
proportion of patients with intractable epilepsy.5 Recently, cannabis 
has attracted attention as a potential treatment of epilepsy.7 
Cannabis was used to treat epilepsy in Sumeria as early as 1800 
BCE.7,8 In the late 19th century, English neurologists also used can-
nabis for the treatment of epilepsy.9-11 More recently, some states in 
America have approved medical marijuana for the treatment of 
epilepsy. Moreover, since 2013, the effects of cannabidiol (CBD) in 
the treatment of epilepsy have been studied at 10 epilepsy centers 
using Epidiolex, a purified cannabis containing 99% CBD and less 
than 0.10% tetrahydrocannabinol (THC). (GW Pharmaceuticals, 
Sativex, London, UK).
Cannabis contains more than 545 distinct compounds, the most 
abundant of which are cannabinoids.12 The most important neuro-
active components of cannabis are CBD and Δ9-THC. THC binds to 
G-protein-coupled cell membrane receptors, including the cannabi-
noid receptor type 1 (CB1R), which is found primarily in the brain, but 
is also present in peripheral tissues, and the cannabinoid receptor 
type 2 (CB2R), which is located mainly in immune and hematopoietic 
cells. THC binds CB1R in inhibitory gamma-aminobutyric acid-ergic 
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Figure 1. Cannbidiol mechanism and structure. CB1R, cannabinoid receptor
type 1; CB2R, cannabinoid receptor type 2; GPR 55, G-protein-coupled
receptor 55; TRPV1-4, transient receptor potential cation channel subfamily
V 1-4;TRPVM8, transient receptor potential cation channel subfamily M 8; 
5HT3AR, 5-hydroxytryptophan type 3A receptor.
Study Age (year) Dose Group (n) Results Reference
Retrospective, parent 
survey in pediatric 
refractory epilepsy
6-13 19 Complete seizer freedom: 2 patients 
More than 80% reduction in seizure 
frequency: 8 patients 
25-60% seizure reduction in seizure 
frequency: 6 patients
Porter and 
Jacobson33
Retrospective, 12- month 
trial for refractory 
epilepsy in tuberous 
sclerosis complex
3-29 Maximum dose of 
50 mg/kg/day
18 The 50% responder rates were 50 % 
after 12 months.
Hess et al.25
Retrospective, open label, 
12- week trial in 
refractory epilepsy
1-22.2 Maximum dose of 
25 or 50 mg/kg/day
162 More than 50% reduction in seizure 
frequency: 51 patients 
More than 70% reduction in seizure 
frequency: 30 patients
More than 90% in seizure frequency: 
11 patients. 
Devinsky et al.23
Table 1. Study in cannabidiol in the treatment of epilepsy
and excitatory glutamatergic neurons.13,14 These interactions are the 
pathways by which cannabis exerts its psychoactive function. 
However, CBD is an antagonist to CB1R and CB2R.15 Some animal 
studies show that CB1R antagonists can reduce the threshold of 
seizures.16 This suggests that CBD has another mechanism by which 
it can control seizures. Indeed, CBD acts via multiple mechanisms 
(Fig. 1).7,14,15 These include effects on transient receptor potential  
ation channels at a low level,17 and antagonistic functions at G-pro-
tein-coupled receptor 55, by which it can decrease presynaptic gluta-
mate release.18 However, the mechanisms underlying the anti-
epileptic effects of CBD are not well defined. 
CBD is metabolized by the liver, and it can inhibit cytochrome P 
(CYP) 450, especially CYP 2C and CYP 3A, which aids metabolism of 
several AED.19,20 Therefore, if a patient with epilepsy takes CBD with 
an enzyme-inducing AED, such as carbamazepine or phenytoin, the 
AED can reduce serum CBD levels. Whereas, if the patient takes clo-
bazam (CLB) with CBD, CBD can raise the serum level of nor-
oclobazam, the active metabolite of CLB.21 The half-life of CBD in hu-
mans is estimated to be between 18 and 32 hours.22
Here, we review recent trials that have investigated the use of CBD 
as a treatment for epilepsy and highlight key issues for future 
research.
Trial dosages of CBD
In many studies, CBD was added to a baseline AED at an initial 
dose of 2-5 mg/kg/day divided into two doses. CBD was up-titrated 
by 2-5 mg/kg once a week until intolerance or to reach a maximal 
dose of 25 mg/kg/day. Some studies increased the does to 50 
mg/kg/day, as allowed by the US Food and Drug Administration. The 
average of dose of CBD was 200-300 mg/day.7
Clinical trials of CBD to treat epilepsy 
Some U.S. states now allow the use of cannabis for medical 
treatment. Many patients with epilepsy have wanted to try cannabis 
as a treatment even though preclinical and clinical evidence is 
limited. As mentioned above, several clinical studies have inves-
tigated CBD after the late 19th century. Recent studies have shown 
an effect of CBD in treating epilepsy (Table 1). They suggest that CBD 
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Reference Devinsky et al.23 (n = 162) Hess et al.
25 (n = 18) Porter et al.33 (n = 19)
Drowsiness 41 (25) 8 (44) 7 (37)
Behavioral problem - 6 (31) 1 (16)
Change in appetite 45 (28) 1 (5.6) -
Diarrhea 31 (19) 4 (22.2) -
Fatigue 21 (13) - 3 (16)
Convulsion 18 (11) - -
Status epilepticus 13 (8) - -
Lethargy 12 (7) - -
Weight increased 12 (7) - -
Weight decreased 10 (6) - -
Ataxia  9 (6) 5 (27.8) -
Increased self-stimulation - 1 (5.6) -
Values are presented as number (%).
Table 2. Adverse events of cannabidiol
can reduce the frequency of seizures, reducing monthly frequency in 
most types of seizures. Many studies have included a significant 
number of patients with Dravet syndrome (DS) and Lennox-Gastaut 
syndrome (LGS), and have observed reduced seizures as an effect of 
CBD. 
Between 2014 and 2015, Devinsky et al.23 conducted a pro-
spective, open-label, and expanded trial at 11 epilepsy centers in 
America. They enrolled 214 patients in the study, of which 137 (64%) 
were included in an efficacy analysis group and 162 (76%) were in-
cluded in a safety analysis group. They observed enrolled patients for 
12 weeks. This study reported a decrease of 34.6% in the median 
change of total seizures after 12 weeks’ treatment with CBD. It also 
showed a decrease of 55% in focal seizures and 54.3% in atonic 
seizures. They observed a decrease of 36.5% and 16% in tonic seiz-
ures and tonic-clonic seizures, respectively. Overall, the median 
monthly frequency of motor seizures decreased by 47%. 
This open-label trial enrolled a large portion of patients with DS 
(n = 32) or LGS (n = 30). In the case of DS, 16 patients (50%) 
showed a reduction in motor seizures of more than 50%, and one 
patient (3%) was free from motor seizures during the 12 weeks of 
treatment. They reported a median change of -69.2% in monthly 
tonic seizures (n = 6) and a median change of -46.7% in monthly 
tonic-clonic seizures (n = 29). Non-motor-focal seizures (n = 10) 
were observed to show a median reduction of 83.3%. Among pa-
tients with LGS (n = 30), 11 (37%) showed a decrease in seizures of 
more than 50%, but none were seizure free during treatment. The 
percentage change in monthly seizures for all seizure types was 
-35.5%. The median change for atonic seizures (n = 14) was 
-68.8%. In patients with tonic seizures (n = 21), there was a median 
reduction of 44.0%. However, there was no change in tonic-clonic 
seizures (n = 16).  
Infantile spasm (IS) is another epileptic encephalopathy in need of 
an effective treatment. In 2014, Hussain et al. conducted a survey 
about CBD exposure,24 which included patients with IS and LGS. 
Although this study had several limitations, it supported the possi-
bility that CBD could effectively treat IS and LGS.  
Hess et al. studied the efficacy of CBD for refractory epilepsy in tu-
berous sclerosis complex (TSC).25 They enrolled 18 patients with epi-
lepsy and TSC between 2014 and 2015, and treated them for 6-12 
months with CBD. In total, 14 patients (77%) had a mutation, half of 
whom had a TSC1 mutation and the other half of whom had a TSC2 
mutation. At baseline, 72% of patients had shown one or more type 
of seizure.25 In this study, the median total weekly seizure frequency 
reduced by 32% after 2 months and 55% after 6 months. At study 
completion after 12 months of treatment, the seizure frequency was 
decreased to 63%. Regarding the CBD effect on each type of seizure, 
epileptic spasms and atonic seizures showed the greatest response. 
The responder rate of tonic-clonic seizures was 66.7% after 3 
months’ treatment. The rates of complex partial seizures and com-
plex partial seizures with secondary generalization were 53.8% and 
50% after 3 months’ treatment, respectively. This study was limited 
by a small sample size, as well as an uncontrolled and unblinded de-
sign, but suggests a potential effect of CBD in TSC.  
Reported adverse effects
In previous studies, the most common adverse effect of CBD was 
drowsiness. Most reported adverse effects were mild, for example di-
arrhea, fatigue, and decreased appetite. Nonetheless, some more se-
rious effects, including status epilepticus, have been reported. 
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Devinsky et al. reported adverse events in 128 (79%) of 162 re-
cruited patients.23 Most of these adverse effects were mild or moder-
ate, and transient. Critical adverse effects considered to be caused by 
CBD were observed in 20 patients (12%).23 The most common ad-
verse event was somnolence, while status epilepticus was the most 
severe and required urgent treatment (Table 2). It is interesting that 
CBD had this severe adverse effect, status epilepticus, because ani-
mal studies have not shown any proconvulsant effects of CBD.9,26 
Devinsky et al. also reported thrombocytopenia in 5 patients (3%), 
but there were no clinical changes in white or red blood cells. CBD 
also did not affect renal function. Ten patients (6%) showed ele-
vated liver enzymes and this elevation was significant in one patient 
(< 1%). The authors did not find any relationship between status 
epilepticus and reduced doses of AED or CBD. Four patients stopped 
CBD treatment before the end of 12 weeks because of a worsening 
of seizures or poor efficacy.  
Discussion
Most studies suggest anticonvulsant effects of CBD, and consider 
most adverse effects to be mild. As such, we might expect CBD to 
show efficacy and safety in the treatment of epilepsy. However, there 
is potential placebo effects biasing these results. In a study by 
Purcarin et al.,27 the placebo effect rate for the reduction of median 
seizure frequency was 10% and the placebo effect was 19% in cases 
in which seizure frequency decreased by 50% or more. According to 
the study of Zaccara et al.,28 greater placebo effects were observed in 
pediatric patients with epilepsy treated with CBD than were in adults. 
A placebo effect is a concern for many studies because of the media 
attention attracted by CBD, which is likely to interest parents of chil-
dren with epilepsy. In most studies, seizure frequency was used as an 
indicator of efficacy. However, to increase the accuracy of proposed 
effects, data from clinical tests, such as electroencephalograms, are 
necessary.   
Due to the absence of a control group in previous studies, the ad-
verse reactions to CBD may also have resulted from a bias. For exam-
ple, many studies reported gastrointestinal problems, such as diar-
rhea and decreased appetite. However, CBD is usually in the form of 
oil, which may have precipitated these effects. Therefore, the adverse 
effects should be reviewed. Furthermore, other adverse effects, such 
as drowsiness, thrombocytopenia, and elevated liver enzymes, also 
require more research to exclude the potential influence of AEDs, 
such as clobazam and valproate. Status epilepticus, the most com-
mon severe adverse effect, was not clearly related to CBD because a 
large proportion of the enrolled patients had refractory epilepsy syn-
dromes, such as LGS, DS and IS. 
CBD not only has potential therapeutic effects on epilepsy, but 
may also be effective in treating various other neurological 
problems.9 In one study, CBD showed antioxidant, anti-inflam-
matory, neuroproliferative, and remyelinating effects.29 While canna-
binoid receptor agonists can reduce hypoxic-ischemic brain injury,29 
lasting overactivation of CB1R can have potential disadvantages. 
However, CBD does not have agonist effects on CB1R and so can be 
an alternative treatment.30 Furthermore, CB2R is one of the primary 
receptors affected by CBD action in the immature brain.30,31 In animal 
studies, CBD has been shown to reduce injury to neurons and as-
trocytes due to hypoxia.31,32 This suggests that neonatal hypoxic is-
chemic encephalopathy could be treated with CBD. This should be a 
focus of future studies. 
One of the most significant limitations of previous studies is their 
open-label, uncontrolled design and the use surveys. Future research 
should use blinded, randomized, controlled trials to confirm the effi-
cacy and adverse effects without bias. Currently, many studies are 
limited to epilepsy, mainly enrolling patients with LGS and DS. 
Further studies of other epilepsy syndromes are also needed in 
future. 
It must be borne in mind that CBD is still illegal in many contexts. 
However, it has the potential to treat various neurological problems, 
including epilepsy. We should seek to clarify the mechanisms under-
lying the antiepileptic effects of CBD and its efficacy for other neuro-
logic problems. Furthermore, drug-drug interactions with AEDs re-
quire further research. Previous studies have determined exact ther-
apeutic drug levels of CBD in the blood. Therefore, this also needs to 
be clarified to enable effective treatment of epilepsy with CBD.
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